| 000 | 01428 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250516110456.0 | ||
| 264 | 0 | _c20130131 | |
| 008 | 201301s 0 0 eng d | ||
| 022 | _a1531-6998 | ||
| 024 | 7 |
_a10.1097/MOO.0b013e328357d2ee _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBlakeley, Jaishri | |
| 245 | 0 | 0 |
_aDevelopment of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma. _h[electronic resource] |
| 260 |
_bCurrent opinion in otolaryngology & head and neck surgery _cOct 2012 |
||
| 300 |
_a372-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aForecasting |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xmethods |
| 650 | 0 | 4 |
_aNeovascularization, Pathologic _xprevention & control |
| 650 | 0 | 4 |
_aNeurofibromatosis 2 _xdrug therapy |
| 650 | 0 | 4 |
_aNeurofibromin 2 _xdrug effects |
| 650 | 0 | 4 |
_aNeuroma, Acoustic _xdrug therapy |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aTOR Serine-Threonine Kinases _xdrug effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tCurrent opinion in otolaryngology & head and neck surgery _gvol. 20 _gno. 5 _gp. 372-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MOO.0b013e328357d2ee _zAvailable from publisher's website |
| 999 |
_c22061476 _d22061476 |
||